has announced that the Food and Drug Administration has
given its Gardasil cervical cancer vaccine priority review
status that will produce a decision on the treatment
Gardasil is an
investigational cervical cancer vaccine designed to
protect against two types of viruses that account for an
estimated 70% of cervical cancer cases and two types
of viruses that account for an estimated 90% of
genital wart cases in both men and women.
A priority review
means the agency will rule on a given drug application
in six months, rather than the standard 10 months. The FDA
told the company it will rule on the application by
submitted the application to the FDA in December, it has
also submitted marketing applications for Gardasil in
Europe, Australia, Mexico, Brazil, Argentina, Taiwan,
has been linked to infection with the sexually
transmitted human papillomavirus, which also can cause
genital and anal warts in women and men. Cervical
cancer also is an AIDS-defining condition among
HIV-positive women. (AP, with additional reporting by
Be sure to follow Advocate on your favorite social platform
DON'T MISS THE OUT100 SPECIAL 3 DAY MARATHON STARTING NOVEMBER 24TH!
Journey through the year’s influential Out100 – the most iconic and long-standing celebration of LGBTQ+ icons and allies – in a 1-hour television special spotlighting the LGBTQ+ people shaping the world today.